Browsing by Author "Arya Devi Ks"

Now showing 1 - 1 of 1

Indian Trial of Tranexamic acid in Spontaneous Intracerebral Hemorrhage study protocol
(SAGE Publications Inc., 2025) Jeyaraj Durai Pandian; Atul Phillips; Shweta Jain Verma; Deepti Arora; Aneesh Dhasan; Pheba Susan Raju; Padmavathyamma Narayanapillai Sylaja; Biman Kanti Ray; Uddalak Chakraborty; Jacob Johnson; Praveen Kumar Sharma; Sanjeev Kumar Bhoi; Menka Jha; Thomas Iype; Chithra P; Dheeraj Khurana; Sucharita Ray; Dwijen Das; Naurima Kalita; Sweekriti Adhikari; Ashish K. Sharma; Jayanta Roy; Rajeshwar Sahonta; Sulena Singh; Vikram Chaudhary; Girish Ramachandran Menon; Sanjith Aaron; Deepti Bal; Rajinder Kumar Dhamija; Monali Chaturvedi; Siddharth Maheshwari; Aralikatte Onkarappa Saroja; Karkal Ravishankar Naik; Neeraj Bhutani; Kailash Dhankhar; Dinesh Sharma; Rohit Bhatia; Sankar Prasad Gorthi; Binod Sarmah; Vijaya Pamidimukkala; Sankaralingam Saravanan; Sunil K. Narayan; Lakshya Jyoti Basumatary; Nagarjunakonda Venkata Sundarachary; Aruna K. Upputuri; Ummer Karadan; Vayyattu Govindankutty Pradeep Kumar; Rajsrinivas Parthasarathy; Darshan Doshi; Satish Wagh; Tirppur C.R. Ramakrishnan; Saleem Akhtar; Soaham Dilip Desai; Nomal Chandra Borah; Rupjyoti Das; Gaurav Kumar Mittal; Agam Jain; Paul J. Alapatt; Girish Baburao Kulkarni; Deepak Menon; Pritam Raja; Inder Puri; Vivek Keshavan Nambiar; Muralidhar Reddy Yerasu; Shyam Krishnakumar Jaiswal; Kapil Gangadhar Zirpe; Sushma Kirtikumar Gurav; Sudheer Sharma; Somasundaram Kumaravelu; M. Bk; Vicky V. Thakkar; Abhishek Pathak; Madhusudhan Byadarahalli Kempegowda; Praveen Chander; Neetu Ramrakhiani; Arya Devi Ks; Prabhakaran Sankara Sarma; Rahul Huilgol; Meenakshi Sharma; Rupinder Singh Dhaliwal
Rationale: Early mortality in intracerebral hemorrhage (ICH) is due to hematoma volume (HV) expansion, and there are no effective treatments available other than reduction in blood pressure. Tranexamic acid (TXA) a hemostatic drug that is widely available and safe can be a cost-effective treatment for ICH, if proven efficacious. Hypothesis: Administration of TXA in ICH patients when given within 4.5 h of symptom onset will reduce early mortality at 30 days. Design: Indian Trial of Tranexamic acid in Spontaneous Intracerebral Haemorrhage (INTRINSIC trial) is a multicenter, randomized, open-label, trial enrolling patients aged more than 18 years presenting with non-traumatic ICH within 4.5 h of symptom onset or when last seen well. Study participants received 2 g of TXA administered within 45 min while control group received standard of care. Intensive blood pressure reduction as per INTERACT 2 protocol is followed is done in both groups. Study plans to recruit 3400 patients. Primary outcome is mortality at day 30. Secondary outcomes are radiological reduction in HV at 24 h from baseline, neurological impairment at day 7 or earlier (if discharged), and assessments of dependency and quality of life at day 90. Summary: If proven to be beneficial, TXA will have a major impact on medical management of ICH. Trial registration: Clinical Trial Registry India (CTRI/2023/03/050224) and Clinical Trials.gov (NCT05836831). © 2025 World Stroke Organization